PDCD1 and adenocarcinoma: Examples of the subgroups lacking adequate sample sizes included the large cell carcinoma (combined with other types of NSCLC than adenocarcinoma and SCC), lung cancer stages I and II (combined together), and immunotherapies other than PD-1/PD-L1 inhibitors (were excluded).